sotalol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
aromatic ring -CH(-OH)-CH2-NH-R 2464 3930-20-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sotalol
  • DL-Sotalol
  • sotalol hydrochloride
  • sotylize
  • sotalol HCl
An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
  • Molecular weight: 272.36
  • Formula: C12H20N2O3S
  • CLOGP: 0.23
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 78.43
  • ALOGS: -2.54
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.16 g O
0.16 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 137 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 85 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 19.57 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.62 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 30, 1992 FDA COVIS PHARMA SARL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Torsade de pointes 340.98 13.68 130 13639 12024 46660269
Atrial fibrillation 331.37 13.68 261 13508 103329 46568964
Electrocardiogram QT prolonged 223.76 13.68 156 13613 51169 46621124
Bradycardia 114.02 13.68 118 13651 66180 46606113
International normalised ratio increased 109.97 13.68 99 13670 46784 46625509
Drug interaction 98.13 13.68 197 13572 202897 46469396
Hyponatraemia 81.22 13.68 123 13646 101209 46571084
Arrhythmia 72.80 13.68 69 13700 34772 46637521
Ventricular tachycardia 67.87 13.68 49 13720 16918 46655375
Ventricular fibrillation 59.70 13.68 39 13730 11457 46660836
Hyperkalaemia 51.57 13.68 69 13700 50640 46621653
Atrial tachycardia 49.95 13.68 20 13749 2100 46670193
Hypotension 45.27 13.68 161 13608 232428 46439865
Erythromelalgia 44.46 13.68 10 13759 137 46672156
Urinary incontinence 44.05 13.68 48 13721 28482 46643811
Ischaemic stroke 40.53 13.68 36 13733 16686 46655607
Atrial flutter 40.23 13.68 28 13741 9120 46663173
Sinus bradycardia 40.20 13.68 33 13736 13749 46658544
Hepatocellular injury 34.43 13.68 43 13726 29479 46642814
Syncope 34.06 13.68 87 13682 104716 46567577
Long QT syndrome 33.72 13.68 17 13752 3063 46669230
Atrioventricular block 32.68 13.68 22 13747 6789 46665504
Rheumatoid arthritis 32.67 13.68 15 13754 240200 46432093
Gastrointestinal haemorrhage 32.49 13.68 71 13698 77302 46594991
Cardiac arrest 32.49 13.68 78 13691 90321 46581972
Palpitations 30.87 13.68 79 13690 95180 46577113
Cardio-respiratory arrest 29.90 13.68 59 13710 59810 46612483
Bundle branch block left 29.11 13.68 20 13749 6379 46665914
Acute kidney injury 27.67 13.68 140 13629 235715 46436578
Haematoma 27.36 13.68 40 13729 31832 46640461
Ventricular arrhythmia 26.50 13.68 15 13754 3406 46668887
Organising pneumonia 26.35 13.68 17 13752 4885 46667408
Apallic syndrome 26.21 13.68 9 13760 614 46671679
Localised oedema 25.83 13.68 17 13752 5052 46667241
Inappropriate antidiuretic hormone secretion 25.83 13.68 26 13743 14076 46658217
Cardiac disorder 25.34 13.68 46 13723 43812 46628481
Loss of consciousness 24.59 13.68 79 13690 108159 46564134
Presyncope 24.42 13.68 33 13736 24421 46647872
Asthenia 24.38 13.68 166 13603 310909 46361384
Cerebral haematoma 24.15 13.68 14 13755 3325 46668968
Pain 23.43 13.68 68 13701 476880 46195413
Malaise 23.19 13.68 172 13597 331060 46341233
Nasal mucosal erosion 22.33 13.68 5 13764 67 46672226
Cardiac failure congestive 21.78 13.68 68 13701 91682 46580611
Livedo reticularis 20.58 13.68 11 13758 2233 46670060
Cardioactive drug level decreased 20.41 13.68 5 13764 101 46672192
Extrasystoles 19.32 13.68 14 13755 4855 46667438
Acute pulmonary oedema 19.14 13.68 17 13752 7874 46664419
Melaena 18.47 13.68 31 13738 27741 46644552
Fall 18.20 13.68 162 13607 328935 46343358
Electrocardiogram QRS complex prolonged 17.92 13.68 14 13755 5435 46666858
Ventricular extrasystoles 17.75 13.68 19 13750 11044 46661249
Off label use 17.31 13.68 56 13713 379785 46292508
Hypokalaemia 17.12 13.68 61 13708 87963 46584330
Muscle haemorrhage 16.64 13.68 11 13758 3293 46669000
Atrioventricular block first degree 16.36 13.68 14 13755 6172 46666121
Sinus node dysfunction 16.27 13.68 12 13757 4277 46668016
Blood pressure increased 16.11 13.68 77 13692 126589 46545704
Blood loss anaemia 16.08 13.68 16 13753 8541 46663752
Electrocardiogram T wave amplitude increased 16.02 13.68 3 13766 15 46672278
Optic nerve infarction 15.16 13.68 3 13766 21 46672272
Haemodialysis 15.09 13.68 16 13753 9201 46663092
Cerebral congestion 15.03 13.68 3 13766 22 46672271
Medication error 14.87 13.68 30 13739 30881 46641412
Left ventricular failure 14.66 13.68 12 13757 4978 46667315
Normocytic anaemia 14.60 13.68 7 13762 1132 46671161
Resting tremor 14.59 13.68 6 13763 674 46671619
Occupational exposure to product 14.57 13.68 8 13761 1713 46670580
Cardioversion 14.52 13.68 7 13762 1145 46671148
Supraventricular extrasystoles 14.43 13.68 11 13758 4118 46668175
Cerebrovascular accident 14.01 13.68 63 13706 100976 46571317
Cardiac ablation 13.93 13.68 7 13762 1252 46671041
Subdural haematoma 13.68 13.68 18 13751 12979 46659314

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Atrial fibrillation 264.87 12.84 280 12959 107844 29831395
Bradycardia 131.21 12.84 153 13086 65373 29873866
Ventricular tachycardia 124.63 12.84 95 13144 23767 29915472
Torsade de pointes 107.95 12.84 56 13183 7134 29932105
Electrocardiogram QT prolonged 100.38 12.84 100 13139 35735 29903504
Cardiogenic shock 89.94 12.84 68 13171 16793 29922446
Atrial flutter 88.38 12.84 63 13176 14218 29925021
Arrhythmia 70.57 12.84 80 13159 33089 29906150
Ventricular arrhythmia 54.78 12.84 30 13209 4258 29934981
International normalised ratio increased 49.19 12.84 81 13158 47658 29891581
Drug interaction 42.85 12.84 188 13051 199380 29739859
Cardiac ablation 38.02 12.84 13 13226 580 29938659
Hypotension 37.17 12.84 181 13058 200384 29738855
Atrial thrombosis 35.15 12.84 17 13222 1864 29937375
Palpitations 34.62 12.84 57 13182 33516 29905723
Apallic syndrome 34.19 12.84 10 13229 266 29938973
Daydreaming 32.88 12.84 11 13228 459 29938780
Staring 32.52 12.84 15 13224 1478 29937761
Petit mal epilepsy 32.48 12.84 18 13221 2613 29936626
Loss of consciousness 30.94 12.84 91 13148 79284 29859955
Haemoptysis 28.39 12.84 50 13189 31028 29908211
Incontinence 27.32 12.84 21 13218 5305 29933934
Ventricular fibrillation 24.79 12.84 32 13207 15106 29924133
Ischaemic stroke 24.49 12.84 33 13206 16242 29922997
Gingival bleeding 23.93 12.84 21 13218 6383 29932856
Drug abuse 23.50 12.84 4 13235 82068 29857171
Dissociation 23.45 12.84 11 13228 1126 29938113
Pallor 23.41 12.84 37 13202 21012 29918227
Xanthopsia 20.39 12.84 6 13233 163 29939076
Presyncope 20.36 12.84 30 13209 16026 29923213
Rectal haemorrhage 18.60 12.84 45 13194 34894 29904345
Long QT syndrome 18.49 12.84 12 13227 2321 29936918
Antiacetylcholine receptor antibody positive 18.35 12.84 4 13235 30 29939209
Cardiac disorder 17.74 12.84 48 13191 39845 29899394
Acquired haemophilia 17.43 12.84 8 13231 779 29938460
Pacemaker generated rhythm 17.24 12.84 4 13235 41 29939198
Hyperplasia 16.88 12.84 7 13232 534 29938705
Dizziness 16.25 12.84 144 13095 194765 29744474
Grandiosity 16.22 12.84 6 13233 337 29938902
Haematuria 16.13 12.84 50 13189 44784 29894455
Transient ischaemic attack 15.10 12.84 34 13205 25166 29914073
Sinus bradycardia 15.04 12.84 22 13217 11673 29927566
Pressure of speech 14.75 12.84 6 13233 436 29938803
Tachycardia induced cardiomyopathy 14.71 12.84 4 13235 81 29939158
Urine flow decreased 14.42 12.84 8 13231 1164 29938075
Heart rate irregular 14.26 12.84 22 13217 12237 29927002
Arrhythmia supraventricular 14.18 12.84 8 13231 1202 29938037
Coagulation factor V level decreased 13.64 12.84 5 13234 274 29938965
Brown-Sequard syndrome 13.18 12.84 3 13236 28 29939211
Dyspnoea 13.02 12.84 213 13026 333082 29606157
Right atrial dilatation 13.02 12.84 5 13234 312 29938927

Pharmacologic Action:

SourceCodeDescription
ATC C07AA07 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, non-selective
ATC C07BA07 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
Beta blocking agents, non-selective, and thiazides
ATC C07FX02 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents, other combinations
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA PE N0000008330 Cardiac Rhythm Alteration
FDA EPC N0000175426 Antiarrhythmic
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013565 Sympatholytics
CHEBI has role CHEBI:35530 beta-adrenoceptor antagonists
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Atrial fibrillation indication 49436004 DOID:0060224
Life-Threatening Ventricular Tachycardia indication
Bronchospasm contraindication 4386001
Complete atrioventricular block contraindication 27885002
Torsades de pointes contraindication 31722008
Sick sinus syndrome contraindication 36083008 DOID:13884
Anaphylaxis contraindication 39579001
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Sinus bradycardia contraindication 49710005
Diabetes mellitus contraindication 73211009 DOID:9351
Cardiogenic shock contraindication 89138009
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Asthma contraindication 195967001 DOID:2841
Impaired renal function disorder contraindication 197663003
Pregnancy, function contraindication 289908002
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.95 acidic
pKa2 9.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium voltage-gated channel subfamily H member 2 Ion channel BLOCKER Ki 4 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 6.90 WOMBAT-PK CHEMBL
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 6.10 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Kd 6.24 CHEMBL
Beta-2 adrenergic receptor GPCR IC50 5.30 CHEMBL

External reference:

IDSource
4020814 VUID
N0000148334 NUI
D01026 KEGG_DRUG
959-24-0 SECONDARY_CAS_RN
4020779 VANDF
4020814 VANDF
C0037707 UMLSCUI
CHEBI:63622 CHEBI
CHEMBL471 ChEMBL_ID
CHEMBL1700 ChEMBL_ID
D013015 MESH_DESCRIPTOR_UI
5253 PUBCHEM_CID
7297 IUPHAR_LIGAND_ID
2350 INN_ID
DB00489 DRUGBANK_ID
A6D97U294I UNII
1593726 RXNORM
230116 MMSL
31427 MMSL
5503 MMSL
d00371 MMSL
003453 NDDF
004111 NDDF
125691000 SNOMEDCT_US
372911006 SNOMEDCT_US
96301002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1060 TABLET 120 mg ORAL ANDA 25 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1061 TABLET 80 mg ORAL ANDA 25 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1062 TABLET 160 mg ORAL ANDA 25 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1063 TABLET 240 mg ORAL ANDA 25 sections
Sorine HUMAN PRESCRIPTION DRUG LABEL 1 0245-0012 TABLET 80 mg ORAL ANDA 28 sections
Sorine HUMAN PRESCRIPTION DRUG LABEL 1 0245-0013 TABLET 120 mg ORAL ANDA 28 sections
Sorine HUMAN PRESCRIPTION DRUG LABEL 1 0245-0014 TABLET 160 mg ORAL ANDA 28 sections
Sorine HUMAN PRESCRIPTION DRUG LABEL 1 0245-0015 TABLET 240 mg ORAL ANDA 28 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-5552 TABLET 80 mg ORAL ANDA 24 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7888 TABLET 80 mg ORAL ANDA 21 sections
Sotalol HUMAN PRESCRIPTION DRUG LABEL 1 10135-661 TABLET 80 mg ORAL ANDA 24 sections
Sotalol HUMAN PRESCRIPTION DRUG LABEL 1 10135-662 TABLET 120 mg ORAL ANDA 24 sections
Sotalol HUMAN PRESCRIPTION DRUG LABEL 1 10135-663 TABLET 160 mg ORAL ANDA 24 sections
Sotalol HydrochlorideAF HUMAN PRESCRIPTION DRUG LABEL 1 10135-715 TABLET 80 mg ORAL ANDA 24 sections
Sotalol HydrochlorideAF HUMAN PRESCRIPTION DRUG LABEL 1 10135-716 TABLET 120 mg ORAL ANDA 24 sections
Sotalol HydrochlorideAF HUMAN PRESCRIPTION DRUG LABEL 1 10135-717 TABLET 160 mg ORAL ANDA 24 sections
sotalol hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-397 TABLET 80 mg ORAL ANDA 19 sections
SOTYLIZE HUMAN PRESCRIPTION DRUG LABEL 1 24338-530 SOLUTION 5 mg ORAL NDA 29 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-121 TABLET 80 mg ORAL ANDA 14 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-122 TABLET 120 mg ORAL ANDA 14 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-123 TABLET 160 mg ORAL ANDA 14 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-616 TABLET 80 mg ORAL ANDA 25 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-1299 TABLET 80 mg ORAL ANDA 25 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-724 TABLET 80 mg ORAL ANDA 25 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-725 TABLET 120 mg ORAL ANDA 25 sections
Sotalol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53217-011 TABLET 80 mg ORAL ANDA 21 sections
sotalol hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-4435 TABLET 80 mg ORAL ANDA 19 sections
sotalol hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5549 TABLET 160 mg ORAL ANDA 19 sections
sotalol hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5614 TABLET 120 mg ORAL ANDA 19 sections
Sorine HUMAN PRESCRIPTION DRUG LABEL 1 55154-5616 TABLET 80 mg ORAL ANDA 19 sections